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Factor Group Number Percent
Age Younger than 35 years 100 10%
35-45 330 33%
45-55 400 40%
Older than 55 years 170 17%
Weight 40-60kg 340 34%
60-80 590 59%
More than 80 70 7%
Marriage Married 920 92%
Single 80 8%
Abortion Yes 380 38%
No 620 62%
History of cervix/vagina
cancer
Yes 140 14%
No 860 86%
OCP consumption Yes 410 41%
No 590 59%
Pain in breast Yes 190 19%
No 810 81%
Swollen lymph nodes Yes 350 35%
No 650 65%
Breast cancer Yes 460 46%
No 450 45%
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were married before the age of 20(51%). The mean marriage age was
18 ± 6 years, the highest age for marriage was at the age of 38 and
between the age of marriage and the cancer, particular relevance was
not found (P ¼ 0.22). In this study, only 8% of women were without
children and 11% of them had no history of breastfeeding, 45% of
themdidn’t have full breastfeeding history. 38%ofwomen had an abor-
tion and that abortion was significantly associated with illness.
In this study, 47% of women had reached menopause, and almost
half of them hadn’t reached the age of menopause and the other half
had reached menopause between the ages of 45 to 50 years. Almost
52% of women experienced breast discharge that almost 70% of them
were bloody discharge that has a significant relationship with breast
cancer. Only 15% of them were smokers, 10% of them were alcohol
consumer. 14% of the subjects had a history of cancer of the cervix
and vagina, that a significant relationship with breast cancer was
observed (p ¼. 000). The significant correlations between breast can-
cer and factors such as discharge of chronic hemorrhage (p . 001),
family history of breast cancer (p .000), age (p ¼0. 003), weight (p
¼0. 001), economy, abortion and history of breast cancer on other
breast were observed.
Conclusion: The results indicate prevalence of 46% of risk factors
for breast cancer in women in Qazvin.
In this study there was a significant relationship between stress
and cancer too. Family history of breast cancer, especially a mother,
sister or daughter with breast cancer in a person's own history, having
first childbirth after the age of 35, infertility, early puberty, late men-
opause, obesity after menopause, high consumption of animal fat in
the diet, a history of high radiation to the chest and some benign
breast disease were the most important factors that increase the risk
of breast cancer. But in this study, maternal education level signifi-
cantly decreased the incidence of cancer.
New risk factors such as breast pain, lymph node swelling, lack of
breast feeding and incomplete milking were listed. The relation of this
kind of epidemiological factors have never been discussed in any study.
These results indicate the urgent need for suitable health services and
immediate screening for prevention of this disease in Qazvin.
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Extended Abstract
Introduction: Development of molecular probes that bind specif-
ically and with high affinity to cancer biomarkers is one of the most
important objectives in the early diagnosis and therapy of cancer.
HER2, a very well-known breast cancer biomarker, overexpressed
in roughly 18% to 22% of breast cancer cases
It has been shown that blockade of HER2 signaling by using
HER2 receptor inhibitors leads to a reversal of most HER2 tumori-
genic features. Aptamer targeting HER2 seems to be an invaluable
tool can be used instead of Herceptin which has been used as a
well-tolerated and active first-line treatment in women with HER2
positive breast cancer.
Aptamers are single stranded oligonucleic acid molecules that
bind their targets with high affinity and specificity. The attractive fea-
tures of aptamers make them very good candidates for clinical appli-
cations and ideal alternatives for antibodies in numerous applications.
Aptamers are typically selected from large libraries of random DNA
sequences by a procedure termed systematic evolution of ligands by
exponential enrichment (SELEX). In this study, cell based strategy
called Cell SELEX was employed to enrich DNA aptamers that are
able to identify HER2 positive cells and HER2 protein in its natural
conformation. In this paper we have addressed main challenges for
the cell SELEX technique. We have also developed a new method,
cell enzyme-linked aptamer based assay, we named it “Cell ELABA”,
as an alternative to flow cytometry to monitor the enrichment of
aptamers in different rounds of cell SELEX.
Materials and methods: Cell Lines: Human breast cancer cell
lines SK-BR-3 and MDA-MB-468 were obtained from the Pasture
Institute of Iran and cultured at 37 C and 5% CO2 in RPMI 1640
medium (Gibco) supplemented with 10% FBS and 100 IU/ml penicil-
lin-streptomycin (Gibco).
SELEX library and primers: The HPLC-purified library and pri-
mers were synthesized by MWG/ Operon (Ebersberg, Germany). The
library and primers used in our study were described in details in our
previous paper.
Cell SELEX procedure: To select aptamers targeting HER2 we
used a HER2 overexpressing breast cancer cell line, SK-BR3. To
avoid the enrichment of aptamers for abundant nonspecific proteins,
a HER2 negative breast cancer cell line, MDA-MB468, was used
from second round in a counter-selection step. Cell-based SELEX
method with some modification used in our studies were described
in detail in our previous paper.
Cell enzyme-linked aptamer based assay (Cell ELABA) mon-
itoring analysis.
500 pmole of biotinylated ssDNA-bound sequences in 500 mL
binding buffer were incubated with cells in the culture flask at 4C
for 60 minutes. After incubation, cells were washed with 3 ml of
washing buffer three times (10 min each), and then incubated with
Fig. 1. Binding assay of the selected pool with SK-BR3 and MDA-MB468
cells using Cell ELABA. For the SKBR3 cells, there was an increase in bind-
ing capacity of the pool as the selection was progressing, whereas there was
little change for the control MDA-MB468 cells.
Fig. 3. Optimization of PCR amplification cycles to analyze the eluted DNA
pool. Amplification products from the PCR reaction of the DNA pool from
the 10th round of SELEX have been shown, where various cycles of PCR
were performed. The location of 76 bp DNA bands in 5% agarose gel is com-
pared with the low-range DNA ladder (Fermentas SM1191). Lane 1, low-range
DNA ladder (Fermentas SM1191); lane 2, DNA pool amplified for 15 cycles;
lane 3, DNA pool amplified for 16 cycles; lane 4, DNA pool amplified for 17
cycles; lane 5, DNA pool amplified for 18 cycles; lane 6, DNA pool amplified
for 19 cycles; lane 7, DNA pool amplified for 15 cycles; lane 8, negative con-
trol. As the figure illustrates, the optimum cycle for PCR amplification was 17
cycles. Additional cycles converted product to by-products.
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in binding buffer). After 45 min incubation at 4C, the enzyme was
washed away. This was a critical step for good performance. Cells
were then scraped and counted. For every 200,000 cells, 100 micro
liter of TMB (Sigma) were added to a 15 ml falcon tube. Cells
were resuspended in TMB, immediately transferred to the 96- well-
plate and the color reaction was read at 490 nM using a Microplate
Reader (Bio-Tek Instruments ELx800).
Gene expression analysis: The expression of HER2 in SK-BR3
and MDA-MB468 cell lines at the mRNA and protein levels were
evaluated by RT-PCR and Western Blot analysis as described in our
previous research.
Result: With increasing stringency during the successive rounds
of SELEX, we expected to achieve a pool of high affinity aptamersFig. 2. Western blot analyses of p185HER2/neu expression. Cell lysate aliquots
containing equal amount of protein (20m) from MDA-MB468 (Lane1) and SK-
BR3 (Lane 2) cell line resolved onto an 8% SDS-PAGE, immunoblotted with
HER2 monoclonal antibody, Neu (3B5) and visualized using ECL HRP color
system. SK-BR3 cell lysate (Lane 4) and MDA-MB468 cell lysate (Lane5)
were immunoprecipitated with anti-HER2 mAb and the precipitated product
resolved onto an 8% SDS- PAGE, immunoblotted with HER2 monoclonal
antibody Neu (3B5) and visualized using ECL HRP color system. SK-BR3
cell lysate depleted of HER2 protein after immunoprecepitation confirm the
procedure quality.for our target HER2 overexpressing cell line. In fact, in the final
cycles of selection we found a considerable enrichment of DNA
sequences which had a high affinity for binding to HER2 overex-
pressing cell line, SK-BR3, and very low affinity for binding to
the control cell line, MDA-MB468. After 16 rounds of selection,
the binding affinity of selected pool reached a plateau indicating a
successful evolution of high affinity aptamers for target cells. No
significant changes were observed during the last two successive
rounds. So that the selection procedure was terminated at this stage
(Figure 1).
We confirmed the expression status of HER2 in SK-BR3 and
MDA-MB468 cell lines at the protein (figure 2) and mRNA levels.
Discussion: In recent years, cell-based SELEX technology has
been successfully applied to develop molecular probes in order to
detect cancer cells and to discover cancer biomarkers. In the present
study, we carried out 16 rounds of Cell SELEX to generate an
enriched pool of candidate aptamers for a HER2 overexpressing
cell line. We considered five important technical points essentials
for a successful selection procedure addressed in our previous paper.
The most critical point among them is high PCR amplification effi-
ciency and enough randomization of library. Our findings confirmed
the results of previous study suggesting that standard procedures of
PCR amplification of homogeneous DNA samples cannot be applied
to the PCR amplification of random DNA libraries (Figure3). In fact,
to ensure an efficient SELEX process, PCR has to be optimized for
the amplification of random DNA libraries. Cell ELABAwas success-
fully developed and adopted in this study to monitor SELEX pro-
gress. The routine method for monitoring successive rounds of
SELEX is flow cytometry. However, Cell ELABA is a very precise,
fast, practical and simple method which can be carried out in labs
with basic equipment, and thus, may be considered as a valuable
alternative. This method would not only be useful for cell-based
SELEX, but also can be employed in all experiments using live
cell ELISA.
Table 1 Reaction setup.
FAS e 670A/G
lmVolume ebased
FAS e 1377 G/A
lmVolume ebased
1 1 Genomic DNA(100ng)
0.4 0.4 dNTP(0.2mm)
2 2 PCR buffer(10x)
0.6 0.6 MgCl2 (25mm)
0.8 0.8 Reverse Primer( 10pmol)
0.8 0.8 Forward Primer( 10pmol)
1 1 Taq DNA polymerase(5 U/mL)
13.4 13.4 Deionised H2O
20 20 Total
Fig. 1. Restriction digestion analysis of PCR products with and on 17% acryl-
amid gel. A: FAS-1377G/A Lane1: AA homozygote with 122 bp; Lane 2, 3:
GG homozygote with 104 bp; Lane 4, 5: GA heterozygote genotype with
122 bp and 104 bp .Size marker of DNA (50 bp ladder). B: FAS-670 A/G
Lane1: AG heterozygote genotype with 193 bp and 136 bp, Lane 2: 136 bp
GG homozygote and lane 3, 4:193 bp AA homozygote respectively; Size
marker of DNA (100 bp ladder).
Table 2 Thermocycling conditions for PCR.
1377- 670-
Temperature (C) Time Temperature (C) Time
Initial denaturation
for 1 cycle
94 2 min 94 2 min
Denaturation 94 30 s 94 30 s
Annealing 69 30 s 62 30 s
Extension 72 45 s 72 45 s
Go to step 2 for
35 cycles
Final extension 72 min 7 72 min 7
15Abstracts - 1st International Nastaran Cancer Symposium-2015 / Journal of Cellular Immunotherapy 1 (2015) 1e45In summary, our results indicate that the generated pool is
enriched of aptamer candidates for HER2 overexpressing cell line.
These results also suggest that cell ELABA can be confidently used
as an alternative method over flow cytometry to monitor SELEX
progress.
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Extended Abstract
Introduction: There are more than 18 sub-types of breast cancer.-
This type of cancer is the second cause of mortality in women. The
etiology of breast cancer is multi factorial. Genetic factors are
involved in the etiology of breast cancer. The FAS gene has a critical
role in tumor growth and metastasis. Two polymorphisms have been
identified in the FAS promoter region in the silencer region, G to A
substitution at nucleotide position 1377 (rs2234767), and the other
in the enhancer region, A to G substitution at nucleotide position
670 (rs1800682). These polymorphisms have been shown to change
the transcription activities of FAS gene. In the present study, we
aimed to determine the linkage disequilibrium between -670 A>G
and -1377 G>A polymorphisms in FAS gene in patients with breast
cancer and controls.
Materials and methods: We carried out a case-control genetic
study in a population selected from Omid Cancer Hospital of Mash-
had in north - eastern part of Iran during the period from February
2013 - October 2014. This study involved a group of 115 female
patients with histologically-confirmed breast cancer and 115 healthy
controls with negative medical history. DNA was extracted by DNA
extraction kit. Spectrophotometry and 1% agarose gel electrophoresis
methods were used to determine quality of the extracted DNA. The
primer sequences were as follows:
FAS -1377 G/A: F 50-TGTGTGCACAAGGCTGGCGC -30
FAS -1377 G/A: R 50-TGCATCTGTCACTGCACTTACCACCA- 3
FAS -670 A/G: F 50- ATAGCTGGGGCTATGCGATT-30
FAS -670 A/G: R 50-CATTTGACTGGGCTGTCCAT-30
These target sequences were amplified according to the recipe in
Table1. PCR amplifications were conducted in Personal Cycler™
amplificator (Biometra, Germany). Thermal cycling conditions are
shown in Table 2. 4 mL of PCR products were digested overnight
at 37C in a 10 mL reaction volume containing 1 units of BstuI and
ScrfI (Fermentas, Germany) were recruited as endonuclease enzymesto detect -1377G/A and -670A/G gene polymorphisms, respectively.
After overnight digestion, solutions were analyzed on 17% acryla-
mide gel and then visualized with silver-nitrate staining (Fig. 1).
Statistical analysis: The statistical analysis of the data was per-
formed by using the SPSS 18.0 software. Genotypes and alleles
were compared between groups by use of c2 test. The strength of
the association between the polymorphisms and cancer risk was
measured by odds ratios (ORs) with 95% confidence intervals
(CIs). The allele frequencies of 2 polymorphisms in case and control
groups followed Hardy-Weinberg’s law of Equilibrium (P > 0.05).
Result: The frequencies of the two alleles in breast cancer patients
were compared with the frequencies in the healthy control subjects. In
the same order , GG, GA and AA genotype frequencies for FAS -1377
polymorphism in patients were 30.4%, 49.6% and 20%, whereas in
control groups were 26.1%, 50.4% and 23.5%, and there was no sig-
nificant difference between case and control groups. Furthermore,
genotype frequencies of FAS -670 AA, AG and GG in patients
were 52.2%, 39.1% and 8.7% respectively. The result of genotype fre-
quencies in control groups for FAS -670 AA, AG and GG were 47%,
